Atox Bio Reports Positive Tissue Infection Trial Results
11/20/2012 7:34:19 AM
More...
|
FDA Grants Fast Track Designation to Atox Bio's AB103 for the Treatment of Necrotizing Soft Tissue Infections (NSTI)
9/10/2012 9:23:06 AM
More...
|
Atox Bio Raises $3.25 Million to Advance Development of AB103, a Novel Therapy for the Treatment of Severe Bacterial Infections, Currently in Phase 2 Clinical Trials
12/19/2011 7:23:02 AM
More...
|
Atox Bio Granted Orphan Drug Designation for AB103 for the Treatment of Necrotizing Soft Tissue Infections (NSTI)
10/25/2011 10:03:36 AM
More...
|
Atox Bio Announces Successful Completion of Phase 1 for AB103, a Novel Immunomodulator Being Developed for Severe Bacterial Infections and Sepsis
5/12/2011 9:34:51 AM
More...
|
Atox Bio Announces Dosing of the First Subject in Its Phase 1 Study of AB103
9/14/2010 12:30:20 PM
More...
|
Atox Bio and Fast-Track Drugs & Biologics Sign an R&D Collaboration Agreement for the Development of Therapeutics for Sepsis and Septic Shock
6/24/2009 9:15:58 AM
More...
|